Grant Bishop

Tuesday, 10 November 2026 · Markets closed · Edition 20

The Index › Metabolic medicine › Whose sales may the drugs grow?

TJX

TJX

TJX runs off-price apparel and home-goods stores such as T.J. Maxx and Marshalls, drawing shoppers with discounted brand-name merchandise rather than making the goods itself. We follow it because weight-loss drugs and health trends may change how much clothing and home goods people buy.

Checked against the company's own business description in its latest annual filing. · entry updated 2026-10-19
Ticker
TJX
Exchange
—
Price
—
Change
—
As of
—
Market cap
—
EV/EBIT
—
P/E NTM
—
FCF yield
—
Net debt/EBITDA
—
Next earnings
—

Last refreshed from 10-Q filed (EDGAR)

Follow · Add to calendar · Daily window

The living report

Bears on our standing view that AI's economy-wide productivity lift does not arrive before 2028. It is proved wrong if productivity jumps much sooner than we expect, or adoption stops spreading.

last revised 19 Oct 2026 · next scheduled disclosure 18 Nov 2026 · results for the quarter ending Oct 2026
The full report

Members: queues this company for a report on a coming night.

The market record

Free during the preview. Each figure shows only where two independent data providers, Massive and Yahoo, agree on it to the cent; a figure they do not agree on is left out. Dated, not live. It describes; it does not recommend.

Last close$138.13
close of 9 Nov 2026 · Massive and Yahoo agree
The day's range$136.00 – $138.37
9 Nov 2026 · both providers agree
52-week range$122.78 – $170.00
intraday low 16 Sep 2026 · intraday high 11 Jun 2026 · 251 sessions to 9 Nov 2026 · both providers agree
Market value$151.9 billion
the 9 Nov 2026 close × 1,099,974,061 shares outstanding on the 10-Q cover, as of 21 Aug 2026
$

Enter any price. The page shows the multiple on the forward estimate on file and where that price sits in the 52-week range. It computes; it does not recommend.

Filings

Newest first, from EDGAR. Where a piece read a filing, one line of what it said.

20 Oct 20268-K · period ending 15 Oct 2026
17 Sep 20268-K · period ending 16 Sep 2026
28 Aug 202610-Q · period ending 1 Aug 2026
19 Aug 20268-K · period ending 19 Aug 2026
11 Jun 20268-K · period ending 9 Jun 2026
29 May 202610-Q · period ending 2 May 2026
20 May 20268-K · period ending 20 May 2026
31 Mar 202610-K · period ending 31 Jan 2026
25 Feb 20268-K · period ending 25 Feb 2026
2 Dec 202510-Q · period ending 1 Nov 2025
19 Nov 20258-K · period ending 19 Nov 2025
29 Aug 202510-Q · period ending 2 Aug 2025
20 Aug 20258-K · period ending 20 Aug 2025
13 Jun 20258-K · period ending 10 Jun 2025
30 May 202510-Q · period ending 3 May 2025
21 May 20258-K · period ending 21 May 2025
9 May 20258-K · period ending 9 May 2025
2 Apr 202510-K · period ending 1 Feb 2025
26 Feb 20258-K · period ending 26 Feb 2025
3 Feb 20258-K · period ending 31 Jan 2025
4 Dec 202410-Q · period ending 2 Nov 2024
20 Nov 20248-K · period ending 20 Nov 2024

Where it sits in the frame

Reports next

18 Nov 2026 · expected, per Nasdaq · results, quarter to Oct 2026

What it bears on

Latest disclosed

10-Q · filed 2026-08-28 · period ending 2026-08-01

Read the filing

Machine-readable

/index/TJX.json

What it has disclosed

Newest first. Every figure traces to a filing; "Show sources" shows which.

—No figure from this company appears in a committed piece yet.

Mentioned in

Every piece that names this company, newest first: what it said, and the standing view it bore on. Written when the piece is committed; never edited, never removed.

—No piece names this company yet.

Same question

Other companies under Whose sales may the drugs grow?

This entry

19 Oct 2026Entry rewritten in plain words: what the company sells, and why we follow it.
12 Oct 2026Verified against the 10-Q filed 2026-08-28 at launch.

Prices on this page are dated market records, shown free during the preview, each confirmed by two independent data providers. None is a recommendation.

Follow TJX. The weekly piece, and a note when a filing moves it.

Record

Written according to the Grant Bishop standard — machine-researched, machine-checked, human-judged; then read and committed by the publisher. Every number traces to a filing or a dated market record; every claim carries a date and what would prove it wrong.

Verification
multi-source verified, machine-drafted, human-gated
As of
2026-08-28
Position disclosure
The publisher holds index-level U.S. equity exposure and no direct position in any single name discussed.
Not advice
General commentary for a general audience. Not advice for your situation.
Sources (12)